The immunizer should be more effective against not only the original variant of the virus, but also against Delta and Omicron
THE National Health Surveillance Agency (Anvisa) and the Butantane Institute met, this Friday 9, to discuss the development of a possible trivalent vaccine against covid-19🇧🇷 According to the agency, the idea is that the vaccine is more effective not only against the original variant of the coronavirus, but also against the Delta and the Omicron (BA.1)🇧🇷
During the meeting, the bodies analyzed the information on an updated version of Legislative Decree coronavirusproduced by Chinese biopharmaceutical sinovac🇧🇷 According to Butantan, so far the data on this production is still preliminary, as Sinovac has only conducted two preclinical studies. The tests have only been carried out on animals, but Sinovac is already recruiting volunteers to proceed with the human testing phase.
Also during the meeting, the Anvisa technical team took the opportunity to point out which points must be observed in a future request for authorization of the trivalent vaccine against covid-19. The criteria for demonstrating the safety and efficacy of the new vaccine were also discussed. So far, however, there is still no application for authorization or clinical study of new versions of Coronavac in Brazil.
The Butantan Institute has been involved in formalising, with Anvisa, the data currently available on the new vaccine and also the planning proposed by Sinovac regarding the next phases of the clinical studies. The regulatory agency must then review the proposals.
Coronavac was the first vaccine against covid-19 to be applied on the national territory, on the initiative of the Butantan Institute in collaboration with Sinovac. In January 2021, the monovalent version, which protects against the original variant of the coronavirus, was temporarily and urgently authorized in Brazil. Currently, the application is allowed from 3 years old.
Recently, Anvisa has approved the use of Pfizer bivalent vaccines, which demonstrate higher efficacy against Omicron (original and BA.1 strain). The first batch of immunizer arrived in Brazil this Friday 9, with 1.4 million doses.
The shipment delivered this Friday will still be analyzed and evaluated by the National Institute for Quality Assurance in Healthcare (INCQS)🇧🇷 Second Ministry of Healththe guidelines on the distribution, application and target of these doses will be communicated through a technical note that will be issued in the next few days.
🇧🇷The best content in your email for free. Choose your favorite Terra newsletter. Click here!
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
